Skip to main content

Advertisement

Fig. 4 | Clinical and Translational Allergy

Fig. 4

From: Standardization of double blind placebo controlled food challenge with soy within a multicentre trial

Fig. 4

Cumulative dose levels of soy protein at occurrence of first signs and symptoms. Objective signs (ObjS) occurred in 58/82 (70.7%) and subjective symptoms (SubjS, either single or sum type) in 70/82 (85.4%) DBPCFC+ patients, respectively. SubjS to soy challenge meal started at significantly lower dose levels than ObjS (p < 0.001). Cumulative threshold dose eliciting objS and subjS in 50% of subjects (ED50) can be extrapolated

Back to article page